Goldman Sachs
LXEO icon

Goldman Sachs’s Lexeo Therapeutics LXEO Stock Holding History

Goldman Sachs’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.2M Buy
1,949,885
+1,168,030
+149% +$8.28M ﹤0.01% 2978
2025
Q4 		$7.76M Buy
781,855
+639,453
+449% +$5.84M ﹤0.01% 3334
2025
Q3 		$946K Buy
142,402
+106,034
+292% +$513K ﹤0.01% 5064
2025
Q2 		$146K Sell
36,368
-42,740
-54% -$141K ﹤0.01% 5746
2025
Q1 		$275K Sell
79,108
-11,793
-13% -$52.2K ﹤0.01% 5507
2024
Q4 		$598K Buy
90,901
+14,150
+18% +$111K ﹤0.01% 5139
2024
Q3 		$694K Buy
76,751
+49,898
+186% +$595K ﹤0.01% 4872
2024
Q2 		$431K Buy
26,853
+3,294
+14% +$47.8K ﹤0.01% 4910
2024
Q1 		$369K Buy
+23,559
New +$368K ﹤0.01% 4879

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.71B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return